ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
This is a 16-week, single center, randomized, double-blind, active-controlled,
parallel-group, Phase 3b efficacy and safety study of simultaneous administration of
saxagliptin 5 mg plus dapagliflozin 10 mg once daily (QD) compared with dapagliflozin plus
placebo for saxagliptin, and placebo for saxagliptin plus placebo for dapagliflozin in
patients with Type 2 diabetes who have inadequate glycemic control on metformin or
metformin/sulfonylurea.
Phase:
N/A
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio